Kenvue Inc. (KVUE) — Analysis Summary
Kenvue Inc. (KVUE) has a market cap of $34.25B with year-over-year revenue growth of -2.1%. Net margin stands at 9.7%. The stock trades at a P/E ratio of 20.7.
Key Takeaways
- Revenue changed -2.1% year-over-year
- Net margin of 9.7%
- P/E ratio of 20.7
Compared to other companies in the PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS sector, KVUE posted revenue growth of -2.1% and trades at a P/E of 20.7.
Kenvue Inc. (KVUE)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Sector
PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS
Employees
22,000
Headquarters
SUMMIT, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 3yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.84
Dividend Yield
4.71%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.